UBS Group
RUBY

UBS Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

UBS Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,300
Closed -$618K – 10416
2021
Q2 		$618K Buy
25,300
+1,500
+6% +$37.5K ﹤0.01% 4563
2021
Q1 		$631K Buy
+23,800
New +$348K ﹤0.01% 4690

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

UBS Group's RUBY Position: Q1 2023 in Review

UBS Group sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 72,662 shares — an estimated $13.1K sold.

UBS Group first reported a position in RUBY in Q3 2018 and held it in 15 quarters. The position peaked at $1.46M in Q3 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • UBS Group reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 72,662 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $13.1K.
  • UBS Group first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 15 quarters.
  • UBS Group's Rubius Therapeutics, Inc position peaked at $1.46M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.